Coronado Biosciences Announces Presentation of Interim Data From Autism Study at Neuropsychopharmacology Meeting

  • Study Investigator Eric Hollander, M.D., Reports Potential Benefits of TSO Immunotherapy in First 5 Patients
  • Study Completion and Final Results Expected Mid-2014

Coronado Biosciences, Inc. (CNDO), a biopharmaceutical company developing novel immunotherapy agents for the treatment of autoimmune diseases and cancer, today announced that Dr. Eric Hollander, Clinical Professor of Psychiatry and Behavioral Sciences at Albert Einstein College of Medicine of Yeshiva University and Director of the Autism and Obsessive Compulsive Spectrum Program at Montefiore Medical Center and Einstein, presented interim data from his pilot study of oral TSO (Trichuris suis ova or CNDO-201) to treat autism at the American College of Neuropsychopharmacology Annual Meeting in Hollywood, Florida.

Read more: Coronado Biosciences Inc ( CNDO )

Cangene To Be Acquired By Emergent BioSolutions For US$222 Million

Cangene Shareholders to Receive US$3.24 Per Share (C$3.44 Per Share) in Cash

Readers are referred to the cautionary notes regarding Forward-looking Information and non-IFRS Financial Measures at the end of this release. Unless noted otherwise, all dollar amounts are in U.S. dollars.

Cangene Corporation ("Cangene") (TSX:CNJ.TO - News) today announced the signing of a definitive agreement under which Emergent BioSolutions ("Emergent") (NYSE:EBS - News) of Rockville, Maryland will acquire Cangene in an all-cash transaction valued at US$222 million (approximately C$236 million1).

Under the terms of the agreement, which has been approved by the Boards of Directors of both companies, Cangene shareholders will receive US$3.24 per share (C$3.44 per share) in cash.

Read more: Cangene Corporation ( CNJ )

FDA Grants Fast Track Designation to Navidea Biopharmaceuticals’ Lymphoseek® for Sentinel Lymph Node Detection in Patients with Head and Neck Cancer

– Fast-Track designation may expedite supplemental New Drug Application (sNDA) approval process –

Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today that the US Food and Drug Administration (FDA) has granted Fast Track designation to Lymphoseek® (technetium 99m tilmanocept) Injection for sentinel lymph node detection in patients with head and neck cancer.

Read more: Navidea Biopharmaceuticals ( NAVB )

Synthetic Biologics Enters into License with Cedars-Sinai Medical Center to Develop Novel Anti-infective Approaches for Irritable Bowel Syndrome (IBS), Obesity and Diabetes

Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of product candidates focused on the prevention and treatment of serious infectious diseases and other diseases, announced today that it entered into worldwide license and option agreements with Cedars-Sinai Medical Center ("Cedars-Sinai") for the development of new treatment approaches to target non-bacterial intestinal microorganism life forms known as archaea that are associated with intestinal methane production and chronic diseases such as irritable bowel syndrome (IBS), obesity and type 2 diabetes, through its newly formed subsidiary, Synthetic Biomics, Inc.

Read more: Synthetic Biologics Inc ( SYN )

Prana Completes PBT2 Dosing in IMAGINE Alzheimer's Disease Clinical Trial

95% Patient Retention Level Achieved in IMAGINE Trial

Prana Biotechnology (ASX: PBT) (NASDAQ: PRAN), a developer of best-in-class treatments for neurodegenerative disease, today announced the completion of the treatment phase of its IMAGINE Alzheimer's Disease (AD) clinical trial.

There were 42 patients with prodromal or mild AD enrolled in the Phase II double-blind placebo-controlled clinical trial of Prana's novel drug, PBT2. A total of 40 patients completed the planned 12 months of treatment with PBT2, or placebo, bringing the treatment phase of the trial to a close.

Read more: Prana Biotechnology ( PRAN )